178 related articles for article (PubMed ID: 36579994)
1. Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.
E Abdelaziz H; El-Guendy N; Radwan EM; Sharawi SK; El-Houseini ME; Abdel-Wahab AA
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4125-4135. PubMed ID: 36579994
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
4. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
Song Y; Xing H; Zhou L; Zhang N; Yang M
Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
[TBL] [Abstract][Full Text] [Related]
5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.
Li R; Xu T; Wang H; Wu N; Liu F; Jia X; Mi J; Lv J; Gao H
Biochem Biophys Res Commun; 2019 Nov; 519(2):358-365. PubMed ID: 31519321
[TBL] [Abstract][Full Text] [Related]
7. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
[TBL] [Abstract][Full Text] [Related]
8. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
[TBL] [Abstract][Full Text] [Related]
9. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
[TBL] [Abstract][Full Text] [Related]
10. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
11. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
[TBL] [Abstract][Full Text] [Related]
12. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
13. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
[TBL] [Abstract][Full Text] [Related]
14. miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma.
Liu J; Yan J; Zhou C; Ma Q; Jin Q; Yang Z
Tumour Biol; 2015 Jan; 36(1):219-25. PubMed ID: 25230788
[TBL] [Abstract][Full Text] [Related]
15. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
16. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
19. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
[TBL] [Abstract][Full Text] [Related]
20. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.
El-Halawany MS; Ismail HM; Zeeneldin AA; Elfiky A; Tantawy M; Kobaisi MH; Hamed I; Abdel Wahab AH
Biomed Res Int; 2015; 2015():649750. PubMed ID: 25811030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
